Commerzbank Aktiengesellschaft FI Has $15.94 Million Holdings in Becton Dickinson and Co (NYSE:BDX)

Commerzbank Aktiengesellschaft FI increased its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 19.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 63,263 shares of the medical instruments supplier’s stock after buying an additional 10,195 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Becton Dickinson and were worth $15,943,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of BDX. Ronna Sue Cohen grew its holdings in Becton Dickinson and by 24,129.0% during the first quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock worth $5,734,000 after purchasing an additional 5,710,365 shares during the period. Thoroughbred Financial Services LLC grew its holdings in Becton Dickinson and by 25,302.2% during the second quarter. Thoroughbred Financial Services LLC now owns 990,940 shares of the medical instruments supplier’s stock worth $99,094,000 after purchasing an additional 987,039 shares during the period. FMR LLC grew its holdings in Becton Dickinson and by 5.0% during the first quarter. FMR LLC now owns 17,835,000 shares of the medical instruments supplier’s stock worth $4,453,934,000 after purchasing an additional 842,590 shares during the period. JPMorgan Chase & Co. grew its holdings in Becton Dickinson and by 10.4% during the first quarter. JPMorgan Chase & Co. now owns 4,418,870 shares of the medical instruments supplier’s stock worth $1,103,526,000 after purchasing an additional 416,459 shares during the period. Finally, California Public Employees Retirement System boosted its holdings in shares of Becton Dickinson and by 29.9% during the first quarter. California Public Employees Retirement System now owns 971,355 shares of the medical instruments supplier’s stock worth $242,576,000 after acquiring an additional 223,484 shares during the period. 84.80% of the stock is currently owned by institutional investors and hedge funds.

BDX traded down $2.42 during trading on Friday, hitting $249.93. 4,674 shares of the stock traded hands, compared to its average volume of 712,455. Becton Dickinson and Co has a twelve month low of $208.62 and a twelve month high of $265.87. The firm has a market cap of $67.33 billion, a P/E ratio of 22.67, a price-to-earnings-growth ratio of 1.91 and a beta of 1.12. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.59 and a current ratio of 0.96. The business’s 50 day moving average is $249.95.

Becton Dickinson and (NYSE:BDX) last announced its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.02. The company had revenue of $4.20 billion during the quarter, compared to the consensus estimate of $4.25 billion. Becton Dickinson and had a net margin of 5.88% and a return on equity of 14.58%. The company’s revenue for the quarter was down .6% compared to the same quarter last year. During the same period in the prior year, the business earned $2.65 earnings per share. On average, analysts forecast that Becton Dickinson and Co will post 11.68 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be paid a $0.77 dividend. The ex-dividend date of this dividend is Friday, September 6th. This represents a $3.08 annualized dividend and a dividend yield of 1.23%. Becton Dickinson and’s dividend payout ratio is 27.97%.

A number of equities research analysts have recently issued reports on BDX shares. Raymond James boosted their price objective on Becton Dickinson and from $265.00 to $288.00 and gave the stock a “strong-buy” rating in a report on Friday, June 28th. KeyCorp restated an “overweight” rating and set a $262.00 price objective (down previously from $273.00) on shares of Becton Dickinson and in a report on Friday, May 10th. BMO Capital Markets reduced their price objective on Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating for the company in a report on Friday, May 10th. Morgan Stanley boosted their price objective on Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 16th. Finally, Zacks Investment Research upgraded Becton Dickinson and from a “sell” rating to a “hold” rating in a report on Monday, May 20th. Six investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Becton Dickinson and currently has an average rating of “Buy” and an average price target of $263.58.

In other Becton Dickinson and news, EVP Patrick Kaltenbach sold 191 shares of the company’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $241.03, for a total transaction of $46,036.73. Following the sale, the executive vice president now owns 19,072 shares of the company’s stock, valued at $4,596,924.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Betty D. Larson sold 1,700 shares of the company’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $224.97, for a total transaction of $382,449.00. Following the sale, the executive vice president now directly owns 11,493 shares in the company, valued at approximately $2,585,580.21. The disclosure for this sale can be found here. In the last three months, insiders sold 21,154 shares of company stock worth $4,955,775. 0.12% of the stock is currently owned by insiders.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: Stock Portfolio Tracker

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.